BioSpace News Archive

Crinetics Pharmaceuticals, Inc. announced that on February 10, 2023, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 90,000 shares of its common stock to six new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan.

Tetra Bio-Pharma Inc. announced that its common shares began trading on the OTC Markets Group’s OTCPink Market in the United States under the symbol “TBPMF” effective at the opening of trading on Friday, February 10, 2023 and will continue to trade on the Toronto Stock Exchange under the ticker symbol “TBP”.

Mirum Pharmaceuticals, Inc. announced that on February 10, 2023, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 5,000 shares of common stock and 2,500 restricted stock units to one new employee under Mirum’s 2020 Inducement Plan.

Evotec SE and the European Investment Bank announced that the EIB has granted Evotec an unsecured loan facility of € 150 m to support the Company’s R&D activities, equity investments and the building of the new J.POD ® biologics manufacturing facility on Evotec’s Campus Curie in Toulouse, France.

Freeline Therapeutics Holdings plc announced the closing of the previously announced sale of its CMC-focused German subsidiary, Freeline Therapeutics GmbH, along with certain related intellectual property, to Ascend Gene and Cell Therapies Ltd., for $25 million, subject to purchase price adjustments.

Azenta, Inc. (Nasdaq: AZTA) today announced that Company management will participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 15-16, 2023.

Pharmazz, Inc. (“Pharmazz”), a biopharmaceutical company focused on developing and commercializing novel therapeutics to treat patients in critical care, presented positive results of its Phase III clinical trial evaluating sovateltide as a treatment for acute ischemic stroke.

Palatin Technologies, Inc. will announce its second quarter fiscal year 2023 operating results on Wednesday, February 15, 2023, before the open of the U.S. financial markets.

Crinetics Pharmaceuticals (Nasdaq: CRNX) today announced that company management will participate in a fireside chat at the annual SVB Securities Global Biopharma Conference, which is being held in a virtual format February 14-16, 2023.

VYNE Therapeutics Inc., a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, announced that its Board of Directors has approved a reverse stock split of the Company’s common stock at a ratio of 1-for-18.